Richard Nolan Townsend Sells 55,000 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 55,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the transaction, the chief executive officer directly owned 340,106 shares of the company’s stock, valued at approximately $1,935,203.14. This represents a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Richard Nolan Townsend also recently made the following trade(s):

• On Wednesday, February 18th, Richard Nolan Townsend sold 10,173 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $6.38, for a total value of $64,903.74.

Lexeo Therapeutics Trading Up 9.4%

Shares of LXEO stock traded up $0.54 during trading on Tuesday, hitting $6.31. The company’s stock had a trading volume of 1,144,943 shares, compared to its average volume of 1,065,644. The business has a fifty day moving average of $6.55 and a 200-day moving average of $7.98. Lexeo Therapeutics, Inc. has a 52 week low of $1.75 and a 52 week high of $10.99. The company has a market cap of $467.51 million, a PE ratio of -2.88 and a beta of 1.99.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. As a group, research analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in LXEO. Allworth Financial LP raised its position in shares of Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after buying an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after buying an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $37,000. California State Teachers Retirement System raised its position in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after buying an additional 2,148 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in shares of Lexeo Therapeutics in the second quarter worth $50,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Raymond James Financial assumed coverage on Lexeo Therapeutics in a report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 price objective for the company. HC Wainwright reduced their price objective on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Chardan Capital restated a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, January 13th. Finally, Oppenheimer restated an “outperform” rating and set a $20.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.88.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.